Airway Epithelium Senescence as a Driving Mechanism in COPD Pathogenesis

Abstract

Cellular senescence is a state of permanent cell cycle arrest triggered by various intrinsic and extrinsic stressors. Cellular senescence results in impaired tissue repair and remodeling, loss of physiological integrity, organ dysfunction, and changes in the secretome. The systemic accumulation of senescence cells has been observed in many age-related diseases. Likewise, cellular senescence has been implicated as a risk factor and driving mechanism in chronic obstructive pulmonary disease (COPD) pathogenesis. Airway epithelium exhibits hallmark features of senescence in COPD including activation of the p53/p21WAF1/CIP1 and p16INK4A/RB pathways, leading to cell cycle arrest. Airway epithelial senescent cells secrete an array of inflammatory mediators, the so-called senescence-associated secretory phenotype (SASP), leading to a persistent low-grade chronic inflammation in COPD. SASP further promotes senescence in an autocrine and paracrine manner, potentially contributing to the onset and progression of COPD. In addition, cellular senescence in COPD airway epithelium is associated with telomere dysfunction, DNA damage, and oxidative stress. This review discusses the potential mechanisms of airway epithelial cell senescence in COPD, the impact of cellular senescence on the development and severity of the disease, and highlights potential targets for modulating cellular senescence in airway epithelium as a potential therapeutic approach in COPD.

From Bronchial Asthma to Tuberculosis: Unravelling the Cytokine-Macrophage Axis in Diverse Diseases

“…49 The development of novel imaging modalities with the potential to visualize these activities in real time holds immense promise for advancing our understanding of inflammation and the immune response, paving the way for the development of more targeted and effective therapeutic strategies. 50,51…”

Unlocking the Future: Pluripotent Stem Cell-Based Lung Repair

“…Depending on the disease, different cell lineages may be required for cellular therapy of the lung (Table 1). While in PAH, ECs [70] and SMCs [71] represent the affected and potentially disease-causing cells, different epithelial cell types and resident epithelial stem/progenitor cells, as well as ECs and SMCs, are discussed as disease-causing respiratory cell lineages in COPD [72,73]. Whereas cells of the proximal airways, including ciliated airway epithelium, goblet cells, and basal cells that allow regeneration of these cells, are considered as disease-causing/target cell types in cystic fibrosis [74] and primary ciliary dysplasia [36,75], type II alveolar epithelial cells seem to play a decisive role not only in inborn surfactant deficiencies [39] but also in pulmonary fibrosis [76].…”

Targeting accelerated pulmonary ageing to treat chronic obstructive pulmonary disease‐induced neuropathological comorbidities

“…The hallmarks of ageing can be categorised into two areas: those affecting cellular processes (such as cellular senescence, stem cells exhaustion and altered intercellular and intracellular communication), and those affecting metabolism (including mitochondrial dysfunction, loss of proteostasis, and dysregulated nutrient sensing) (López‐Otín et al, 2013 ; Meiners et al, 2015 ). The effects of accelerated ageing in COPD lungs has been eloquently reviewed elsewhere (see Barnes et al, 2019 ; Bateman et al, 2023 ; Brandsma et al, 2017 ). Briefly, in the lungs of patients with COPD, there is an accumulation of senescent cells including alveolar epithelial cells, endothelial cells, pulmonary artery smooth muscle cells as well as fibroblasts overexpressing markers of senescence such as p16 (also known as p16INK4a, cyclin‐dependent kinase inhibitor 2A, CDKN2A), p21 (cyclin‐dependent kinase inhibitor 1) and senescence‐associated beta‐galactosidase (SA‐β‐gal) (Amsellem et al, 2011 ; Noureddine et al, 2011 ; Tsuji et al, 2006 ; Woldhuis et al, 2021 ).…”